B cell-ablative therapy: Where are we now?

International Journal of Immunopathology and Pharmacology

Volumn 20, Issue 4, 2007, Pages 655-659

  Bordron, A ^a   Mankai A ^a,b   Bendaoud, B ^a   Saraux, A ^a   Devauchelle, V ^a   Ghedira, I ^b   Jamin, C ^a   Pers, J C ^a   Berthou, C ^a   Youinou, Pierre ^a,c  

^a Universite de Brest   (France)

^b UNIVERSITY OF MONASTIR   (Tunisia)

^c FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

Author keywords

Anti CD20 antibody; CD20; Chronic lymphocytic leukemia autoimmunity; Malignant lymphoproliferative diseases; Systemic lupus erythematosus

Indexed keywords

B LYMPHOCYTE ANTIBODY; CD20 ANTIBODY; DOXORUBICIN; RITUXIMAB; TETANUS ANTIBODY; TETANUS TOXOID;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; BRONCHOSPASM; CANCER CELL; CELL PROLIFERATION; CLINICAL TRIAL; DEPLETION; DRUG EFFICACY; DRUG FEVER; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; GRAFT REJECTION; HEADACHE; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNOTHERAPY; LABORATORY TEST; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; SEPSIS;

EID: 37749048475     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200702000401     Document Type: Review

References (30)

1. Youinou P. 2007. B cell conducts the lymphocyte orchestra. J. Autoimmun. 28:143.
2. Pitashny M. and Y. Shoenfeld. 2005. B cell depletion in autoimmune rheumatic diseases. Autoimmun. Rev. 4:436.
3. Maloney D.G. 2001. Mechanism of action of rituximab. Anticancer Drugs 12:S1.
4. McLaughlin P., A.J. Grillo-Lopez, B.K. Link, R. Levy, M.S. Czuczman, M.E. Williams, M.R. Heyman, I. Bence-Bruckler, C.A. White, F. Cabanillas, V. Jain, A.D. Ho, J. Lister, K. Wey, D. Shen and B.K. Dallaire. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16:2825.
5. Withers D.R., C. Fiorini, R.T. Fischer, R. Ettinger, P.E. Lipsky and A.C. Grammer. 2007. T cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue. Blood 109:4856.
6. Anolik J., R.J. Looney, A. Bottaro, I. Sanz and F. Young. 2003. Down-regulation of CD20 on B cells upon CD40 activation. Eur. J. Immunol. 33:2398.
7. Cragg M.S., S.M. Morgan, H.T. Chan, B.P. Morgan, A.V. Filatov, P.W. Johnson, R.R. French and M.J. Glennie. 2003. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101:1045.
8. Pedersen I.M., A.M. Buhl, P. Klausen, C.H. Geisler and J. Jurlander. 2002. The chimeric anti-CD20 antibody rituximab induces apoptosis in B CLL cells through a p38 MAP-kinase-dependent mechanism. Blood 99:1314.
9. Takei K., T. Yamazaki, U. Sawada, H. Ishizuka and S. Aizawa. 2006. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk. Res. 30:625.
10. Cartron G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 and polymorphism in FcgammaRIIIa gene. Blood 99:754.
11. Kennedy A.D., P.V. Beum, M.D. Solga, D.J. DiLillo, M.A. Lindorfer, C.E. Hess, J.J. Densmore, M.E. Williams and R.P. Taylor. 2004. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in CLL. J. Immunol. 172:3280.
12. Beum P.V., A.D. Kennedy, M.E. Williams, M.A. Lindorfer and R.P. Taylor. 2006. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and CLL cells by THP-1 monocytes. J. Immunol. 176:2600.
13. Reff M.E., K. Carner, K.S. Chambers, P.C. Chinn, J.E. Leonard, R. Raab, R.A. Newman, N. Hanna and D.R. Anderson. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435.
14. Pers J.O., V. Devauchelle, C. Daridon, B. Bendaoud, R. Le Berre, A. Bordron, P. Hutin, Y. Renaudineau, M. Dueymes, S. Loisel, C. Berthou, A. Saraux and P. Youinou. BAFF-modulated repopulation of B lymphocytes and salivary glands of rituximab-treated patients with Sjögren's syndrome. 2007. Arthritis Rheum. 56:1464.
15. Gong Q., Q. Ou, S. Ye, W.P. Lee, J. Cornelius, L. Diehl, W.Y. Lin, Z. Hu, Y. Lu, Y. Chen, Y. Wu, Y.G. Meng, P. Gribling, Z. Lin, K. Nguyen, T. Tran, Y. Zhang, H. Rosen, F. Martin and A.C. Chan. 2005. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174:817.
16. Edwards J.C., L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D.R. Close, R.M. Stevens and T. Shaw. 2004. Efficacy of B cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350:2572.
17. Anolik J.H., J. Barnard, A. Cappione, A.E. Pugh-Bernard, R.E. Felgar, R.J. Looney and I. Sanz. 2004. Rituximab improves peripheral B cell abnormalities in human SLE. Arthritis Rheum. 50:3580.
18. Pijpe J., G.W. van Imhoff, F.K. Spijkervet, J.L. Roodenburg, G.J. Wolbink, K. Mansour, A. Vissink, C.G. Kallenberg and H. Bootsma. 2005. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum. 52:2740.
19. Cooper N., R. Stasi, S. Cunningham-Rundles, M.A. Feuerstein, J.P. Leonard, S. Amadori and J.B. Bussel. 2004. The efficacy and safety of B cell depletion with anti-CD20 in adults with CTP. Br. J. Haematol. 125:232.
20. Anolik J.H., J.W. Friedberg, B. Zheng, J. Barnard, T. Owen, E. Cushing, J. Kelly, E.C. Milner, R.I. Fisher and I. Sanz. 2007. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontongeny. Clin. Immunol. 122:139.
21. Looney R.J., J.H. Anolik, D. Campbell, R.E. Felgar, F. Young, L.J. Arend, J.A. Sloand, J. Rosenblatt and I. Sanz. 2004. B cell depletion as a novel treatment for SLE: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50:2580.
22. Cambridge G., M.J. Leandro, J.C. Edwards, M.R. Ehrenstein, M. Salden, M. Bodman-Smith and A.D. Webster. 2003. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48:2146.
23. Winkler U., M. Jensen, O. Manzke, H. Schulz, V. Diehl and A. Engert. 1999. Cytokine-release syndrome in patients with B-CLL and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody. Blood 94:2217.
24. Kimby E. 2005. Tolerability and safety of rituximab. Cancer Treat. Rev. 31:456.
25. Maeda T., Y. Yamada, M. Tawara, R. Yamasaki, Y. Yakata, C. Tsutsumi, Y. Onimaru, S. Kamihira and M. Tomonaga. 2001. Successful treatment with a chimeric anti-CD20 antibody for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. Int. J. Hematol. 74:70.
26. Farag S.S., I.W. Flinn, R. Modali, T.A. Lehman, D. Young and J.C. Byrd. 2004. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 103:1472.
27. Wood A.M. 2001. Rituximab: an innovative therapy for non-Hodgkin's lymphoma. Am. J. Health Syst. Pharm. 58:215.
28. Zaja F., N. Vianelli, A. Sperotto, S. De Vita, I. Iacona, A. Zaccaria, P. Masolini, V. Tomadini, M. Tani, A.L. Molinari, M. Baccarani and R. Fanin. 2003. B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 88:538.
29. Keren A., H.M. Hayes and G. O'Driscoll. 2006. Late humoral rejection in a cardiac transplant recipient treated with the anti-CD20 monoclonal antibody rituximab. Transplant. Proc. 38:1520.
30. Usuda M., K. Fujimori, N. Koyamada, T. Fukumori, S. Sekiguchi, N. Kawagishi, Y. Akamatsu, Y. Enomoto, K. Satoh, A. Satoh, K. Ishida, T. Moriya and S. Satomi. 2005. Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation. Transplantation 79:12.